Immune adjuvant activity of pre-resectional radiofrequency ablation protects against local and systemic recurrence in aggressive murine colorectal cancer

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Ito, Fumito ^a,b   Ku, Amy W ^a   Bucsek, Mark J ^a   Muhitch, Jason B ^a   Vardam Kaur, Trupti ^a,c   Kim, Minhyung ^a   Fisher, Daniel T ^a   Camoriano, Marta ^a   Khoury, Thaer ^a   Skitzki, Joseph J ^a   Gollnick, Sandra O ^a   Evans, Sharon S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ANTIGEN; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; FEMALE; FOXP3+ REGULATORY T LYMPHOCYTE; IMMUNE DEFICIENCY; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RADIOFREQUENCY LESION GENERATOR; SPLEEN; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; C57BL MOUSE; CATHETER ABLATION; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PREVENTION AND CONTROL; SURVIVAL ANALYSIS; TUMOR INVASION; TUMOR RECURRENCE;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CATHETER ABLATION; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; LYMPH NODES; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84957921907     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143370     Document Type: Article

References (63)

1. Picardo A, Karpoff HM, Ng B, Lee J, Brennan MF, Fong Y. Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery. 1998;124(1):57-64. Epub 1998/07/15. PMID: 9663252.
2. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818-25; discussion 25-7. Epub 2004/05/29. doi: 00000658-200406000-00009 [pii]. PMID: 15166961; PubMed Central PMCID: PMC1356290.
3. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440-8. Epub 2009/09/05. doi: 10.1097/SLA. 0b013e3181b4539b PMID: 19730175.
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-8. Epub 2002/10/31. doi: 10.1038/ni1102-991 PMID: 12407406.
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-4. Epub 2006/09/30. doi: 313/5795/1960 [pii] doi: 10.1126/science.1129139 PMID: 17008531.
6. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014-22. Epub 2013/09/21. doi: 10.1038/ni.2703 PMID: 24048123; PubMed Central PMCID: PMCPMC4118725.
7. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306. Epub 2012/03/16. doi: 10.1038/nrc3245 PMID: 22419253.
8. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199-208. Epub 2014/02/25. doi: 10.1038/nrc3672 PMID: 24561446.
9. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493-508. Epub 2009/10/21. doi: 10.1200/jco.2009.23. 4450 PMID: 19841322.
10. Evrard S, Poston G, Kissmeyer-Nielsen P, Diallo A, Desolneux G, Brouste V, et al. Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases. PLoSOne. 2014;9(12):e114404. Epub 2014/12/09. doi: 10.1371/journal.pone.0114404 PMID: 25485541; PubMed Central PMCID: PMCPMC4259316.
11. den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer research. 2004;64(11):4024-9. PMID: 15173017.
12. Dromi SA, Walsh MP, Herby S, Traughber B, Xie J, Sharma KV, et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology. 2009;251(1):58-66. Epub 2009/03/03. doi: 2511072175 [pii] doi: 10.1148/radiol.2511072175 PMID: 19251937; PubMed Central PMCID: PMC2663580.
13. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. British journal of cancer. 2006;95(7):896-905. PMID: 16953240.
14. Wissniowski TT, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B, et al. Activation of tumorspecific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer research. 2003;63(19):6496-500. Epub 2003/10/16. PMID: 14559842.
15. Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer research. 2006;66(2):1139-46. PMID: 16424051.
16. Kim H, Park BK, Kim CK. Spontaneous regression of pulmonary and adrenal metastases following percutaneous radiofrequency ablation of a recurrent renal cell carcinoma. Korean J Radiol. 2008;9(5):470-2. Epub 2008/10/08. doi: 2008v9n5p470 [pii] doi: 10.3348/kjr.2008.9.5.470 PMID: 18838859; PubMed Central PMCID: PMC2627212.
17. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radiofrequency ablation of primary tumor: an in situ tumor vaccine? J Urol. 2003;170(1):178-9. Epub 2003/06/11. doi: 10.1097/01.ju.0000070823.38336.7b PMID: 12796677.
18. Soanes WA, Ablin RJ, Gonder MJ. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol. 1970;104(1):154-9. Epub 1970/07/01. PMID: 4987666.
19. Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, et al. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoSOne. 2013;8(7):e70417. Epub 2013/07/31. doi: 10.1371/journal. pone.0070417 PMID: 23894654; PubMed Central PMCID: PMCPMC3722166.
20. Erosde Bethlenfalva-Hora C, Mertens JC, Piguet AC, Kettenbach J, Schmitt J, Terracciano L, et al. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. Clinical science (London, England: 1979). 2014;126(3):243-52. Epub 2013/07/05. doi: 10.1042/cs20130089 PMID: 23822114.
21. Brackett CM, Muhitch JB, Evans SS, Gollnick SO. IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J Immunol. 2013;191(8):4348-57. Epub 2013/09/13. doi: 10.4049/jimmunol.1103621 PMID: 24026079; PubMed Central PMCID: PMCPMC3795982.
22. Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011;121(10):3846-59. Epub 2011/09/20. doi: 10.1172/JCI44952 44952 [pii]. PMID: 21926464; PubMed Central PMCID: PMC3195455.
23. Johnson EE, Yamane BH, Buhtoiarov IN, Lum HD, Rakhmilevich AL, Mahvi DM, et al. Radiofrequency ablation combined with KS-IL2immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009;15(15):4875-84. Epub 2009/07/30. doi: 1078-0432CCR-09-0110 [pii] doi: 10.1158/1078-0432. CCR-09-0110 PMID: 19638464; PubMed Central PMCID: PMC2735865.
24. Chen Q, Fisher DT, Clancy KA, Gauguet JM, Wang WC, Unger E, et al. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol. 2006;7(12):1299-308. PMID: 17086187.
25. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics Int. 2004;11(7):36-42.
26. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Toonen LW, Figdor CG, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer research. 2006;66(14):7285-92. Epub 2006/07/20. doi: 66/14/7285 [pii] doi: 10.1158/0008-5472. CAN-06-0206 PMID: 16849578.
27. Behm B, Di Fazio P, Michl P, Neureiter D, Kemmerling R, Hahn EG, et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut. 2014. Epub 2014/12/20. doi: 10.1136/gutjnl-2014-308286 PMID: 25524262.
28. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005;102(2):419-24. Epub 2004/12/30. doi: 10.1073/pnas.0408197102 PMID: 15623559; PubMed Central PMCID: PMCPMC544311.
29. Schneider T, Sevko A, Heussel CP, Umansky L, Beckhove P, Dienemann H, et al. Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clinical and experimental immunology. 2015;180(3):467-74. Epub 2015/02/04. doi: 10.1111/cei.12596 PMID: 25644608; PubMed Central PMCID: PMCPMC4449775.
30. Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, et al. Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother. 2013;62(8):1421-30. Epub 2013/06/15. doi: 10.1007/s00262-013-1447-1 PMID: 23764929.
31. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000;165(4):1992-2000. Epub 2000/08/05. doi: ji-v165n4p1992 [pii]. PMID: 10925282.
32. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, et al. Regulatory Tcell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2013;20(3):946-55. Epub 2012/09/27. doi: 10.1245/s 10434-012-2668-9 PMID: 23010736; PubMed Central PMCID: PMCPMC3740360.
33. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234-41. Epub 1953/05/01. PMID: 13042090.
34. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229-35. Epub 2006/01/25. doi: 10.1097/01.sla.0000197706.21803.a1 PMID: 16432356; PubMed Central PMCID: PMCPMC1448919.
35. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214(2):114-7. Epub 1991/08/01. PMID: 1714267; PubMed Central PMCID: PMCPMC1358509.
36. Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153(6):811-8. Epub 2013/03/19. doi: 10.1016/j.surg.2012.12.005 PMID: 23499016.
37. Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg. 2009;250(2):210-8. Epub 2009/07/30. doi: 10.1097/SLA.0b013e3181afe0ab PMID: 19638920.
38. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70. Epub 2011/03/26. doi: 10.1126/science. 1203486 PMID: 21436444.
39. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012;22(4):327-34. Epub 2012/04/03. doi: 10.1016/j.semcancer.2012.03.004 PMID: 22465232; PubMed Central PMCID: PMCPMC3385925.
40. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186-92. Epub 2008/12/10. doi: 10.1200/jco.2008.18.7229 PMID: 19064967.
41. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer research. 2011;71(4):1263-71. Epub 2011/02/10. doi: 10.1158/0008-5472.can-10-2907 PMID: 21303976.
42. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, et al. High frequency of tumor-infiltrating FOXP3 (+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer. 2010;126(11):2635-43. Epub 2009/10/27. doi: 10.1002/ijc.24989 PMID: 19856313.
43. Michel S, Benner A, Tariverdian M, Wentzensen N, Hoefler P, Pommerencke T, et al. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. British journal of cancer. 2008;99(11):1867-73. Epub 2008/11/06. doi: 10.1038/sj.bjc.6604756 PMID: 18985040; PubMed Central PMCID: PMCPMC2600708.
44. Yang WL, Nair DG, Makizumi R, Gallos G, Ye X, Sharma RR, et al. Heat shock protein 70 is induced in mouse human colon tumor xenografts after sublethal radiofrequency ablation. Ann Surg Oncol. 2004;11(4):399-406. Epub 2004/04/09. doi: 10.1245/aso.2004.08.013 PMID: 15070600.
45. Liu Q, Zhai B, Yang W, Yu LX, Dong W, He YQ, et al. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. MolTher. 2009;17(12):2049-57. Epub 2009/09/24. doi: 10.1038/mt.2009.221 PMID: 19773743; PubMed Central PMCID: PMCPMC2814395.
46. Rai R, Richardson C, Flecknell P, Robertson H, Burt A, Manas DM. Study of apoptosis and heat shock protein (HSP) expression in hepatocytes following radiofrequency ablation (RFA). The Journal of surgical research. 2005;129(1):147-51. Epub 2005/06/25. doi: 10.1016/j.jss.2005.03.020 PMID: 15975593.
47. Ali MY, Grimm CF, Ritter M, Mohr L, Allgaier HP, Weth R, et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. Journal of hepatology. 2005;43(5):817-22. Epub 2005/08/10. doi: 10. 1016/j.jhep. 2005.04.016 PMID: 16087270.
48. Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, Schivazappa S, et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother. 2008;31(3):271-82. Epub 2008/03/05. doi: 10.1097/CJI.0b013e318160ff1c PMID: 18317360.
49. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. The Journal of experimental medicine. 1997;186(8):1315-22. Epub 1997/10/23. PMID: 9334371; PubMed Central PMCID: PMCPMC2199095.
50. Sharma MD, Hou DY, Baban B, Koni PA, He Y, Chandler PR, et al. Reprogrammedfoxp3 (+) regulatory T cells provide essential help to support cross-presentation and CD8 (+) T cell priming in naive mice. Immunity. 2010;33(6):942-54. Epub 2010/12/15. doi: 10.1016/j.immuni.2010.11.022 PMID: 21145762; PubMed Central PMCID: PMCPMC3032429.
51. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59-73. Epub 2007/12/22. doi: 10.1038/nri2216 PMID: 18097448.
52. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? The oncologist. 2004;9 Suppl 5:31-40. Epub 2004/12/14. doi: 10.1634/theoncologist. 9-90005-31 PMID: 15591420.
53. Izzo F, Thomas R, Delrio P, Rinaldo M, Vallone P, De Chiara A, et al. Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 26 patients. Cancer. 2001;92(8):2036-44. Epub 2001/10/12. PMID: 11596017.
54. Jeffrey SS, Birdwell RL, Ikeda DM, Daniel BL, Nowels KW, Dirbas FM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg. 1999;134(10):1064-8. Epub 1999/10/16. PMID: 10522847.
55. Burak WE Jr, Agnese DM, Povoski SP, Yanssens TL, Bloom KJ, Wakely PE, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer. 2003;98(7):1369-76. Epub 2003/09/26. doi: 10.1002/cncr.11642 PMID: 14508822.
56. Kroeze SG, Daenen LG, Nijkamp MW, Roodhart JM, de Gast GC, Bosch JL, et al. Radiofrequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model. J Urol. 2012;188(2):607-14. Epub 2012/06/19. doi: 10.1016/j.juro.2012.03.116 PMID: 22704448.
57. Iida N, Nakamoto Y, Baba T, Nakagawa H, Mizukoshi E, Naito M, et al. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC Chemokine ligand 3/macrophage inflammatory protein-1alpha. Cancer research. 2010;70(16):6556-65. Epub 2010/07/29. doi: 10.1158/0008-5472.can-10-0096 PMID: 20663902.
58. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. Epub 2012/06/05. doi: 10.1056/NEJMoa1200690 PMID: 22658127; PubMed Central PMCID: PMCPMC3544539.
59. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65. Epub 2012/06/05. doi: 10.1056/NEJMoa1200694 PMID: 22658128; PubMed Central PMCID: PMCPMC3563263.
60. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of experimental medicine. 2010;207(10):2187-94. Epub 2010/09/08. doi: 10.1084/jem.20100643 PMID: 20819927; PubMed Central PMCID: PMCPMC2947065.
61. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer research. 2013;73(12):3591-603. Epub 2013/05/02. doi: 10.1158/0008-5472.can-12-4100 PMID: 23633484; PubMed Central PMCID: PMCPMC3686913.
62. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20. Epub 2015/06/02. doi: 10.1056/NEJMoa1500596 PMID: 26028255; PubMed Central PMCID: PMCPMC4481136.
63. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43-51. Epub 2014/11/02. doi: 10.1158/2159-8290.cd-14-0863 PMID: 25358689; PubMed Central PMCID: PMCPMC4293246.